English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Abstract   Aims  Inhibition of neprilysin and angiotensin II receptor by sacubitril/valsartan (Val) (LCZ696) reduces mortality in heart failure (HF) patients compared with sole inhibition of renin–angiotensin system. Beneficial effects of increased natriuretic peptide levels upon neprilysin inhibition have been proposed, whereas direct effects of sacubitrilat (Sac) (LBQ657) on myocardial Ca 2+  cycling remain elusive.    Methods and results  Confocal microscopy (Fluo‐4 AM) was used to investigate pro‐arrhythmogenic sarcoplasmic reticulum (SR) Ca 2+  leak in freshly isolated murine and human ventricular cardiomyocytes (CMs) upon Sac (40 μmol/L)/Val (13 μmol/L) treatment. The concentrations of Sac and Val equalled plasma concentrations of LCZ696 treatment used in PARADIGM‐HF trial. Epifluorescence microscopy measurements (Fura‐2 AM) were performed to investigate effects on systolic Ca 2+  release, SR Ca 2+  load, and Ca 2+ ‐transient kinetics in freshly isolated murine ventricular CMs. The impact of Sac on myocardial contractility was evaluated using  in toto ‐isolated, isometrically twitching ventricular trabeculae from human hearts with end‐stage HF. Under basal conditions, the combination of Sac/Val did not influence diastolic Ca 2+ ‐spark frequency (CaSpF) nor pro‐arrhythmogenic SR Ca 2  leak in isolated murine ventricular CMs ( n  CMs/hearts = 80/7 vs. 100/7,  P  = 0.91/0.99). In contrast, Sac/Val treatment reduced CaSpF by 35 ± 9% and SR Ca 2+  leak by 45 ± 9% in CMs put under catecholaminergic stress (isoproterenol 30 nmol/L,  n  = 81/7 vs. 62/7,  P  &lt; 0.001 each). This could be attributed to Sac, as sole Sac treatment also reduced both parameters by similar degrees (reduction of CaSpF by 57 ± 7% and SR Ca 2+  leak by 76 ± 5%;  n  = 101/4 vs. 108/4,  P  &lt; 0.01 each), whereas sole Val treatment did not. Systolic Ca 2+  release, SR Ca 2+  load, and Ca 2+ ‐transient kinetics including SERCA activity ( k  SERCA ) were not compromised by Sac in isolated murine CMs ( n  = 41/6 vs. 39/6). Importantly, the combination of Sac/Val and Sac alone also reduced diastolic CaSpF and SR Ca 2+  leak (reduction by 74 ± 7%) in human left ventricular CMs from patients with end‐stage HF ( n  = 71/8 vs. 78/8,  P  &lt; 0.05 each). Myocardial contractility of human ventricular trabeculae was not acutely affected by Sac treatment as the developed force remained unchanged over a time course of 30 min ( n  trabeculae/hearts = 3/3 vs. 4/3).    Conclusion  This study demonstrates that neprilysin inhibitor Sac directly improves Ca 2+  homeostasis in human end‐stage HF by reducing pro‐arrhythmogenic SR Ca 2+  leak without acutely affecting systolic Ca 2+  release and inotropy. These effects might contribute to the mortality benefits observed in the PARADIGM‐HF trial.

esc heart failure

Sacubitrilat reduces pro‐arrhythmogenic sarcoplasmic reticulum Ca 2+  leak in human ventricular cardiomyocytes of patients with end‐stage heart failure